Archives

GLP-1 agonists linked to significantly lower long-term risk of knee replacement

Wednesday, June 3 – GLP-1 receptor agonist drugs, used for the treatment of diabetes—and more recently, weight loss—are associated with a significantly lower long-term risk of knee replacement surgery as a result of osteoarthritis, finds an analysis of medical records data, published in the open-access journal Regional Anesthesia & Pain Medicine.

GLP-1 Drugs Cut Need for Knee Replacement

Wednesday, June 3 – (MedPage Today) — People with knee osteoarthritis (OA) who used GLP-1 receptor agonists were less likely to undergo knee replacement surgery, an analysis of a large records database indicated.
Compared with otherwise similar OA patients not taking…

Existing drug enhances muscle repair during GLP-1 weight-loss treatment in mice

Wednesday, June 3 – Millions of Americans are currently taking GLP-1 medications such as Ozempic or Wegovy for weight loss. But along with the fat, many are quietly losing something else: muscle. Unlike fat, muscle doesn’t return quickly, and muscle loss can have deleterious effects on strength, mobility, and overall health.

GLP-1 use linked to lower breast cancer incidence in large cohort study

Wednesday, June 3 – A retrospective analysis of more than 110,000 women between the ages of 45 and 80 found that those who took GLP-1 medications were about 30% less likely to develop breast cancer than those who did not take GLP-1 medications, according to research presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 10506) by Elizabeth McDonald, MD, Ph.D., a professor of Radiology in the University of Pennsylvania Perelman School of Medicine and a practicing breast radiologist at Penn’s Abramson Cancer Center.

How digital platforms and policy shifts reshape GLP-1 affordability

Wednesday, June 3 – A News and Perspectives report on emerging pharmaceutical access models in the United States has been published in the Journal of Medical Internet Research. In “Affordable GLP-1? When Digital Platforms Meet Policy Reform”, a JMIR Correspondent Xiangming Jenny Zhan investigates how a convergence of federal policy, manufacturer-led digital distribution, and telehealth integration has drastically lowered the cost of GLP-1 medications outside the traditional insurance system.